Glucose targets: TI responds

Issue: BCMJ, vol. 50, No. 5, June 2008, Page 267 Letters
By: James M. Wright, MD, PhD, FRCPC

We thank Drs Ur and Dawson for their comments on the Therapeutics Letter 68 entitled “Gly­cemic targets in type 2 diabetes.” We agree with their conclusion that “the precise glucose target has yet to be identified.” That in fact is one of the main conclusions of Letter 68. 

In addition, we felt that the ACCORD result showing increased mortality in the <6% HbA1C target group was important and compelling enough to justify reporting at this time. 

The following is our response to each of the other points. 

1. The Letter was not meant to be and does not claim to be a systematic review but rather a des­cription of the two most recent trials looking at glycemic targets.

2. The data we quote and the reference we use are on the NIH ACCORD study web site. We accept that the mortality data reported there are valid as the trialists stopped the study because of these results. 

3. It has been a policy of the TI to not include authors of Therapeutics Letter issues; however, this policy is now under review and may change. The authors of all issues of the Therapeutics Letter are available on request. I am the author of Letter 68 and declare no conflicts. Publication of the Therapeutics Letter is made possible by a grant from the BC Ministry of Health. Letter 68 was sent for expert review to three internists, nine family practitioners, three pharmacists, and others. As is common in peer review, we don’t have permission to release reviewers’ names.  

4. We believe that total mortality outweighs microvascular outcomes, but we did not ignore them. The Letter reports the evidence on microvascular outcomes from the UKPDS trial.

—James M. Wright, MD
On behalf of the Scientific Information and Education Committee
Therapeutics Initiative

James M. Wright, MD, PhD, FRCPC. Glucose targets: TI responds. BCMJ, Vol. 50, No. 5, June, 2008, Page(s) 267 - Letters.


Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply